Craig Hallum initiated coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00

B. Riley Securities initiated coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00

Lake Street resumed coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

4/A - Strata Critical Medical, Inc. (0001779128) (Issuer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

8-K - Strata Critical Medical, Inc. (0001779128) (Filer)

25-NSE - Strata Critical Medical, Inc. (0001779128) (Subject)

10-Q - Strata Critical Medical, Inc. (0001779128) (Filer)

8-K - Strata Critical Medical, Inc. (0001779128) (Filer)

SCHEDULE 13G/A - Strata Critical Medical, Inc. (0001779128) (Subject)

DEFA14A - Strata Critical Medical, Inc. (0001779128) (Filer)

DEF 14A - Strata Critical Medical, Inc. (0001779128) (Filer)

10-K - Strata Critical Medical, Inc. (0001779128) (Filer)

8-K - Strata Critical Medical, Inc. (0001779128) (Filer)

8-K - Strata Critical Medical, Inc. (0001779128) (Filer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. ("LPS"), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. "The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and Southern United States," said Lou Verdetto, CEO of Strata's Clinical Division. "More than just unlocking the ability to win new perfusion contracts in the region, LPS also expands the national footpr

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), announced that its warrants, both the Public Warrants (NASDAQ:SRTAW) and the Private Placement Warrants, expired in accordance with their original terms at 5:00 p.m. Eastern Time today May 7, 2026. About Strata Critical Medical, Inc. Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated "one call" solution for donor organ recovery. Strata's core services include

Revenue increased 87.4% year-over-year to $67.4 million in Q1 2026Logistics revenue and gross profit grew 32.4% and 29.9% year-over-year, respectively, in Q1 2026, which represents Strata's organic growthClinical revenue and gross profit sequential growth of 12.7% and 29.2%, respectively in Q1 2026 versus Q4 2025 Q1 2026 net income from continuing operations of $2.4 millionAdjusted EBITDA(1) of $6.4 million in Q1 2026Completed bolt-on acquisition of Ohio Valley Perfusion AssociatesReiterating full year 2026 guidance NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )), today announced financial results for the first quar

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )), today announced that it has completed the acquisition of Ohio Valley Perfusion Associates ("OVPA"), a regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania. "Expanding our presence in Eastern Ohio and Western Pennsylvania is an important step in strengthening Strata's regional clinical platform," said Louis Verdetto, CEO of Strata's Clinical Services Division. "These programs align well with our existing operations and allow us to further leverage our team of highly trained perfusionists to support cardiac surgery programs whil

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the first quarter ended March 31, 2026 on Wednesday May 6, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will be provi

NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 1:30 pm ET. A webcast of the event will be available at the link here. A replay will be available shortly after the conclusion of the presentation on the investor relations section of the Company's website at https://ir.stratacritical.com/. About Strata Critical Medical Strata Critical Medical provides time-critical logistics solutions and specialized medical services to healthcare providers across the United States, strategically expandi

Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata's organic growthFull year 2025 net loss from continuing operations was $20.1 millionFull year 2025 revenue and Adjusted EBITDA(1) of $197.1 million and $14.1 million, respectively, both beat the high end of our guidance rangeRaising full year 2026 revenue guidance to between $260 and $275 million and Adjusted EBITDA guidance to between $29 and $33 million(2) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )), today announced financi

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will be pr

$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditionsOwned aircraft excluded from collateral package and remain unencumbered NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Strata Critical Medical, Inc. ("Strata" or the "Company"), a leading provider of logistics and medical services in the organ transplant industry, today announced the appointment of Will Cook to the Board, effective December 3, 2025. Mr. Cook has also been appointed to the Compensation and Nominating and Corporate Governance Committees. Mr. Cook is the President and Chief Executive Officer of Vail Health, a nonprofit community health care system headquartered in Vail, Colorado. "We are very excited to welcome Will Cook to our board of directors," said Melissa Tomkiel, Strata's Co-Chief Executive Office

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Strata Critical Medical, Inc. ("Strata" or the "Company"), a leading provider of logistics and medical services in the organ transplant industry, today announced the appointment of Will Cook to the Board, effective December 3, 2025. Mr. Cook has also been appointed to the Compensation and Nominating and Corporate Governance Committees. Mr. Cook is the President and Chief Executive Officer of Vail Health, a nonprofit community health care system headquartered in Vail, Colorado. "We are very excited to welcome Will Cook to our board of directors," said Melissa Tomkiel, Strata's Co-Chief Executive Office

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. ("LPS"), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. "The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and Southern United States," said Lou Verdetto, CEO of Strata's Clinical Division. "More than just unlocking the ability to win new perfusion contracts in the region, LPS also expands the national footpr

Revenue increased 87.4% year-over-year to $67.4 million in Q1 2026Logistics revenue and gross profit grew 32.4% and 29.9% year-over-year, respectively, in Q1 2026, which represents Strata's organic growthClinical revenue and gross profit sequential growth of 12.7% and 29.2%, respectively in Q1 2026 versus Q4 2025 Q1 2026 net income from continuing operations of $2.4 millionAdjusted EBITDA(1) of $6.4 million in Q1 2026Completed bolt-on acquisition of Ohio Valley Perfusion AssociatesReiterating full year 2026 guidance NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )), today announced financial results for the first quar

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )), today announced that it has completed the acquisition of Ohio Valley Perfusion Associates ("OVPA"), a regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania. "Expanding our presence in Eastern Ohio and Western Pennsylvania is an important step in strengthening Strata's regional clinical platform," said Louis Verdetto, CEO of Strata's Clinical Services Division. "These programs align well with our existing operations and allow us to further leverage our team of highly trained perfusionists to support cardiac surgery programs whil

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the first quarter ended March 31, 2026 on Wednesday May 6, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will be provi

Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata's organic growthFull year 2025 net loss from continuing operations was $20.1 millionFull year 2025 revenue and Adjusted EBITDA(1) of $197.1 million and $14.1 million, respectively, both beat the high end of our guidance rangeRaising full year 2026 revenue guidance to between $260 and $275 million and Adjusted EBITDA guidance to between $29 and $33 million(2) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )), today announced financi

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will be pr

Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year periodMedical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition(1)Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025(1)Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA rangeInvestor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 1

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the third quarter ended September 30, 2025 on Monday, November 10, 2025 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will b